OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Franco on the Integration of Immunotherapy Treatment in Endometrial Cancer

March 14th 2024

Idalid Franco, MD, MPH, discusses the use of radiation therapy and immunomodulatory agents in the treatment of endometrial cancer.

Dr Plichta on Areas of Interest for Genetic Testing Research in Breast Cancer

March 14th 2024

Jennifer K. Plichta, MD, MS, discusses key areas of interest regarding the role and optimization of genetic testing in breast cancer.

Dr Hwang on the Potential Use of Multicancer Early Detection Tests in Breast Cancer Screening

March 14th 2024

Shelley Hwang, MD, MPH, discusses the potential use of multicancer early detection tests in breast cancer screening.

Dr Pellini on the Clinical Utility of ctDNA Assays in NSCLC

March 13th 2024

Bruna Pellini, MD, discusses the utility of circulating tumor DNA assays in non–small cell lung cancer.

Dr Grajales-Cruz on the Safety of Teclistamab in Multiple Myeloma

March 13th 2024

Ariel F. Grajales-Cruz, MD, discusses the real-world efficacy of teclistamab in relapsed/refractory multiple myeloma.

Dr Rini on the FDA Approval of Belzutifan in Relapsed/Refractory RCC

March 13th 2024

Brian I. Rini, MD, FASCO, shares the importance of the FDA approval of belzutifan in patients with advanced renal cell carcinoma.

Dr Pedersen on the Evolving Use of Cytoreductive Surgery for Peritoneal Carcinomatosis

March 13th 2024

Katrina S. Pedersen, MD, MS, discusses the evolving use of cytoreductive surgery for patients with peritoneal carcinomatosis.

Dr Sartor on PSMA PET and Radioligand Therapy in Prostate Cancer

March 13th 2024

Oliver Sartor, MD, discusses the use of PSMA PET and radioligand therapy in prostate cancer.

Dr Jimenez on the Radiation Treatment Paradigm in Breast Cancer

March 13th 2024

Rachel Jimenez, MD, discusses unmet needs in radiation treatment for patients with breast cancer.

Dr Sartor on Ongoing Prostate Cancer Research

March 13th 2024

Oliver Sartor, MD, discusses ongoing prostate cancer research, highlighting the importance of considering patient quality of life.

Dr Calais on Controversies in the Treatment of Patients With Prostate Cancer

March 13th 2024

Jeremie Calais, MD, PhD, discusses controversies and unresolved questions in the treatment of patients with prostate cancer.

Dr McCann on Navigating Work-Life Balance As a Woman in Oncology

March 12th 2024

Kelly E. McCann, MD, PhD, discusses her experiences with mentorship and work-life balance as a woman in oncology.

Dr Zhang on Topics of Ongoing Debate Within Prostate Cancer

March 12th 2024

Tian Zhang, MD, MHS, discusses areas of ongoing debate regarding prostate cancer management.

Dr Levy on the Potential for ADCs in NSCLC

March 12th 2024

Benjamin Levy, MD, explores the potential role of antibody-drug conjugates in non–small cell lung cancer.

Dr Richter on Proactive Toxicity Management With Bispecific Antibodies in Myeloma

March 12th 2024

Joshua Richter, MD, discusses the role of bispecific antibody therapy in myeloma and expands on toxicity management for these agents.

Dr Agarwal on QOL Considerations for Patients With Prostate Cancer

March 11th 2024

Neeraj Agarwal, FASCO, MD, discusses quality of life considerations for patients with prostate cancer.

Dr Graff on the Trajectory of Her Career in Breast Cancer

March 11th 2024

Stephanie L. Graff, MD, discusses the trajectory of her career growth in breast oncology and explains how different factors can play a role in an oncologist’s career path.

Dr Rugo on Challenges Faced as a Woman in Oncology

March 11th 2024

Hope S. Rugo, MD, discusses challenges that women face in the workplace in oncology care.

Dr Tripathy on the Management of Early-Stage HER2+ Breast Cancer

March 10th 2024

Debu Tripathy, MD, discusses current considerations for the management of early-stage HER2-positive breast cancer.

Dr Rugo on the Evolution of ADCs in HR+/HER2+ and HER2-Low Breast Cancer

March 9th 2024

Hope Rugo, MD, discusses the evolution of antibody-drug conjugates in hormone receptor–positive, HER2-positive, and HER2-low breast cancer.